Quantitative proteomic analysis by iTRAQ® for the identification of candidate biomarkers in ovarian cancer serum

Kristin L Boylan, John D. Andersen, Lorraine B. Anderson, LeeAnn Higgins, Amy P Skubitz

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: Ovarian cancer is the most lethal gynecologic malignancy, with the majority of cases diagnosed at an advanced stage when treatments are less successful. Novel serum protein markers are needed to detect ovarian cancer in its earliest stage; when detected early, survival rates are over 90%. The identification of new serum biomarkers is hindered by the presence of a small number of highly abundant proteins that comprise approximately 95% of serum total protein. In this study, we used pooled serum depleted of the most highly abundant proteins to reduce the dynamic range of proteins, and thereby enhance the identification of serum biomarkers using the quantitative proteomic method iTRAQ®.Results: Medium and low abundance proteins from 6 serum pools of 10 patients each from women with serous ovarian carcinoma, and 6 non-cancer control pools were labeled with isobaric tags using iTRAQ® to determine the relative abundance of serum proteins identified by MS. A total of 220 unique proteins were identified and fourteen proteins were elevated in ovarian cancer compared to control serum pools, including several novel candidate ovarian cancer biomarkers: extracellular matrix protein-1, leucine-rich alpha-2 glycoprotein-1, lipopolysaccharide binding protein-1, and proteoglycan-4. Western immunoblotting validated the relative increases in serum protein levels for several of the proteins identified.Conclusions: This study provides the first analysis of immunodepleted serum in combination with iTRAQ® to measure relative protein expression in ovarian cancer patients for the pursuit of serum biomarkers. Several candidate biomarkers were identified which warrant further development.

Original languageEnglish (US)
Article number31
JournalProteome Science
Volume8
DOIs
StatePublished - Jun 14 2010

Fingerprint

Biomarkers
Proteomics
Ovarian Neoplasms
Blood Proteins
Serum
Proteins
Extracellular Matrix Proteins
Proteoglycans
Tumor Biomarkers
Leucine
Glycoproteins
Survival Rate
Western Blotting
Carcinoma
Neoplasms

Cite this

Quantitative proteomic analysis by iTRAQ® for the identification of candidate biomarkers in ovarian cancer serum. / Boylan, Kristin L; Andersen, John D.; Anderson, Lorraine B.; Higgins, LeeAnn; Skubitz, Amy P.

In: Proteome Science, Vol. 8, 31, 14.06.2010.

Research output: Contribution to journalArticle

@article{5dbe4578884245888376dd756a50d3e1,
title = "Quantitative proteomic analysis by iTRAQ{\circledR} for the identification of candidate biomarkers in ovarian cancer serum",
abstract = "Background: Ovarian cancer is the most lethal gynecologic malignancy, with the majority of cases diagnosed at an advanced stage when treatments are less successful. Novel serum protein markers are needed to detect ovarian cancer in its earliest stage; when detected early, survival rates are over 90{\%}. The identification of new serum biomarkers is hindered by the presence of a small number of highly abundant proteins that comprise approximately 95{\%} of serum total protein. In this study, we used pooled serum depleted of the most highly abundant proteins to reduce the dynamic range of proteins, and thereby enhance the identification of serum biomarkers using the quantitative proteomic method iTRAQ{\circledR}.Results: Medium and low abundance proteins from 6 serum pools of 10 patients each from women with serous ovarian carcinoma, and 6 non-cancer control pools were labeled with isobaric tags using iTRAQ{\circledR} to determine the relative abundance of serum proteins identified by MS. A total of 220 unique proteins were identified and fourteen proteins were elevated in ovarian cancer compared to control serum pools, including several novel candidate ovarian cancer biomarkers: extracellular matrix protein-1, leucine-rich alpha-2 glycoprotein-1, lipopolysaccharide binding protein-1, and proteoglycan-4. Western immunoblotting validated the relative increases in serum protein levels for several of the proteins identified.Conclusions: This study provides the first analysis of immunodepleted serum in combination with iTRAQ{\circledR} to measure relative protein expression in ovarian cancer patients for the pursuit of serum biomarkers. Several candidate biomarkers were identified which warrant further development.",
author = "Boylan, {Kristin L} and Andersen, {John D.} and Anderson, {Lorraine B.} and LeeAnn Higgins and Skubitz, {Amy P}",
year = "2010",
month = "6",
day = "14",
doi = "10.1186/1477-5956-8-31",
language = "English (US)",
volume = "8",
journal = "Proteome Science",
issn = "1477-5956",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Quantitative proteomic analysis by iTRAQ® for the identification of candidate biomarkers in ovarian cancer serum

AU - Boylan, Kristin L

AU - Andersen, John D.

AU - Anderson, Lorraine B.

AU - Higgins, LeeAnn

AU - Skubitz, Amy P

PY - 2010/6/14

Y1 - 2010/6/14

N2 - Background: Ovarian cancer is the most lethal gynecologic malignancy, with the majority of cases diagnosed at an advanced stage when treatments are less successful. Novel serum protein markers are needed to detect ovarian cancer in its earliest stage; when detected early, survival rates are over 90%. The identification of new serum biomarkers is hindered by the presence of a small number of highly abundant proteins that comprise approximately 95% of serum total protein. In this study, we used pooled serum depleted of the most highly abundant proteins to reduce the dynamic range of proteins, and thereby enhance the identification of serum biomarkers using the quantitative proteomic method iTRAQ®.Results: Medium and low abundance proteins from 6 serum pools of 10 patients each from women with serous ovarian carcinoma, and 6 non-cancer control pools were labeled with isobaric tags using iTRAQ® to determine the relative abundance of serum proteins identified by MS. A total of 220 unique proteins were identified and fourteen proteins were elevated in ovarian cancer compared to control serum pools, including several novel candidate ovarian cancer biomarkers: extracellular matrix protein-1, leucine-rich alpha-2 glycoprotein-1, lipopolysaccharide binding protein-1, and proteoglycan-4. Western immunoblotting validated the relative increases in serum protein levels for several of the proteins identified.Conclusions: This study provides the first analysis of immunodepleted serum in combination with iTRAQ® to measure relative protein expression in ovarian cancer patients for the pursuit of serum biomarkers. Several candidate biomarkers were identified which warrant further development.

AB - Background: Ovarian cancer is the most lethal gynecologic malignancy, with the majority of cases diagnosed at an advanced stage when treatments are less successful. Novel serum protein markers are needed to detect ovarian cancer in its earliest stage; when detected early, survival rates are over 90%. The identification of new serum biomarkers is hindered by the presence of a small number of highly abundant proteins that comprise approximately 95% of serum total protein. In this study, we used pooled serum depleted of the most highly abundant proteins to reduce the dynamic range of proteins, and thereby enhance the identification of serum biomarkers using the quantitative proteomic method iTRAQ®.Results: Medium and low abundance proteins from 6 serum pools of 10 patients each from women with serous ovarian carcinoma, and 6 non-cancer control pools were labeled with isobaric tags using iTRAQ® to determine the relative abundance of serum proteins identified by MS. A total of 220 unique proteins were identified and fourteen proteins were elevated in ovarian cancer compared to control serum pools, including several novel candidate ovarian cancer biomarkers: extracellular matrix protein-1, leucine-rich alpha-2 glycoprotein-1, lipopolysaccharide binding protein-1, and proteoglycan-4. Western immunoblotting validated the relative increases in serum protein levels for several of the proteins identified.Conclusions: This study provides the first analysis of immunodepleted serum in combination with iTRAQ® to measure relative protein expression in ovarian cancer patients for the pursuit of serum biomarkers. Several candidate biomarkers were identified which warrant further development.

UR - http://www.scopus.com/inward/record.url?scp=77953339286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953339286&partnerID=8YFLogxK

U2 - 10.1186/1477-5956-8-31

DO - 10.1186/1477-5956-8-31

M3 - Article

C2 - 20546617

AN - SCOPUS:77953339286

VL - 8

JO - Proteome Science

JF - Proteome Science

SN - 1477-5956

M1 - 31

ER -